胃癌及食管胃结合部癌免疫及靶向治疗研究进展

doi:10.3760/cma.j.cn371439-20240716-00099

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (9): 595-600.doi: 10.3760/cma.j.cn371439-20240716-00099

胃癌及食管胃结合部癌免疫及靶向治疗研究进展

伍杨¹^,², 李甜², 张润兵¹^,², 史婷婷¹^,², 高春¹, 郑晓凤³, 张久聪¹()

¹中国人民解放军联勤保障部队第九四〇医院消化内科，兰州 730050
²甘肃中医药大学第一临床医学院，兰州 730000
³兰州大学第二临床医学院消化科，兰州 730030

收稿日期:2024-07-16 修回日期:2024-08-07 出版日期:2024-09-08 发布日期:2024-10-12
通讯作者: 张久聪 E-mail:zhangjiucong@163.com
基金资助:
甘肃省青年科技基金(22JR5RA1012);甘肃省青年科技基金(23JRRA1673);兰州市科技计划项目(2023-2-29)

Research progress in immunotherapy and targeted therapy for gastric cancer and esophagogastric junction cancer

Wu Yang¹^,², Li Tian², Zhang Runbing¹^,², Shi Tingting¹^,², Gao Chun¹, Zheng Xiaofeng³, Zhang Jiucong¹()

¹Department of Gastroenterology， 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army， Lanzhou 730050， China
²First School of Clinical Medical of Gansu University of Traditional Chinese Medicine， Lanzhou 730000， China
³Department of Gastroenterology， Second Clinical Medical School of Lanzhou University， Lanzhou 730030， China

Received:2024-07-16 Revised:2024-08-07 Online:2024-09-08 Published:2024-10-12
Contact: Zhang Jiucong E-mail:zhangjiucong@163.com
Supported by:
Gansu Youth Science and Technology Fund(22JR5RA1012);Gansu Youth Science and Technology Fund(23JRRA1673);Lanzhou Science and Technology Planning Project(2023-2-29)

摘要/Abstract

摘要：

胃癌及食管胃结合部癌（EGJC）是最常见的恶性肿瘤之一，传统治疗方法通常以放化疗及手术治疗为主，但对患者的预后改善有限。近年来随着治疗手段的发展，免疫治疗和靶向治疗逐渐被公认为一线治疗方法。免疫治疗中，纳武利尤单抗和帕博利珠单抗对程序性死亡受体配体1阳性的患者表现出明确疗效，而其他免疫治疗（如肿瘤疫苗、工程化T细胞和非特异性免疫调节剂等）目前仍在试验或研发中。此外，靶向治疗目前仅在某些特定人群或在二线治疗中表现出较大的治疗潜力，如曲妥珠单抗对人表皮生长因子受体2阳性的患者具有明确疗效，而对其他分子靶点扩增的患者疗效欠佳。深入探讨免疫治疗及靶向治疗在胃癌及EGJC中的研究进展，将有助于改善患者预后，并为肿瘤的精准治疗提供参考。

关键词: 胃肿瘤, 食管胃接合处, 免疫疗法, 分子靶向治疗

Abstract:

Gastric cancer and esophagogastric junction cancer （EGJC） are one of the world's most common types of malignant tumors. Traditional treatment methods mainly include radiotherapy， chemotherapy， and surgery， but the patients' prognosis is limited. In recent years， with the development in treatment methods， immunotherapy and targeted therapy are gradually recognized as the first-line treatment methods. In immunotherapy， nivolumab and pabolizumab have shown clear efficacy in patients with programmed death-ligand 1 positive， while other immunotherapies （such as tumor vaccine， engineered T cells， and non-specific immunomodulators） are still being tested or developed. In addition， targeted therapy has only shown comparatively large therapeutic potential in certain specific populations or in second-line treatment. For instance， tratuzumab has a clear curative effect on patients with positive human epidermal growth factor receptor 2， but has suboptimal efficacy in patients with amplification of other molecular targets. An in-depth discussion of the research progress of immunotherapy and targeted therapy in gastric cancer and EGJC will help to improve the prognosis of patients and provide a reference for accurate treatment of tumors.

Key words: Stomach neoplasms, Esophagogastric junction, Immunotherapy, Molecular targeted therapy

伍杨, 李甜, 张润兵, 史婷婷, 高春, 郑晓凤, 张久聪. 胃癌及食管胃结合部癌免疫及靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 595-600.

Wu Yang, Li Tian, Zhang Runbing, Shi Tingting, Gao Chun, Zheng Xiaofeng, Zhang Jiucong. Research progress in immunotherapy and targeted therapy for gastric cancer and esophagogastric junction cancer[J]. Journal of International Oncology, 2024, 51(9): 595-600.

参考文献 44

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Viale PH. The American cancer society's facts & figures: 2020 edition[J]. J Adv Pract Oncol, 2020, 11(2): 135-136. DOI: 10.6004/jadpro.2020.11.2.1.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358. DOI: 10.3760/cma.j.cn371439-20240318-00061.
[4]	Takimoto R, Kamigaki T, Ito H, et al. Safety evaluation of immune-cell therapy for malignant tumor in the cancer immune-cell therapy evaluation group(CITEG)[J]. Cytotherapy, 2023, 25(11): 1229-1235. DOI: 10.1016/j.jcyt.2023.06.007. pmid: 37486281
[5]	Yu Y, Ma X, Zhang Y, et al. Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancer[J]. J Cancer, 2019, 10(12): 2754-2763. DOI: 10.7150/jca.31755. pmid: 31258783
[6]	Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
[7]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2. pmid: 34102137
[8]	Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. DOI: 10.1016/S0140-6736(21)01234-4.
[9]	Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580. DOI: 10.1001/jamaoncol.2020.3370.
[10]	Quesada S, Samalin E, Thezenas S, et al. Perioperative FOLFOX in patients with locally advanced oesogastric adenocarcinoma[J]. Anticancer Res, 2022, 42(1): 185-193. DOI: 10.21873/anticanres.15472. pmid: 34969724
[11]	Liu R, Wang X, Ji Z, et al. Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: a case report[J]. World J Clin Cases, 2022, 10(18): 6184-6191. DOI: 10.12998/wjcc.v10.i18.6184. pmid: 35949814
[12]	Depotte L, Palle J, Rasola C, et al. New developments and standard of care in the management of advanced gastric cancer[J]. Clin Res Hepatol Gastroenterol, 2024, 48(1): 102245. DOI: 10.1016/j.clinre.2023.102245.
[13]	杨柳, 王大榛, 赵璐, 等. 局部晚期胃癌围手术期免疫治疗研究进展[J]. 肿瘤学杂志, 2024, 30(4): 276-285. DOI: 10.11735/j.issn.1671-170X.2024.04.B003.
[14]	Wiedermann U, Garner-Spitzer E, Chao Y, et al. Clinical and immunologic responses to a B-cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer-results from phase Ⅰb trial IMU.ACS.001[J]. Clin Cancer Res, 2021, 27(13): 3649-3660. DOI: 10.1158/1078-0432.CCR-20-3742. pmid: 33879458
[15]	Fucikova J, Hensler M, Kasikova L, et al. An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors[J]. Clin Cancer Res, 2022, 28(14): 3053-3065. DOI: 10.1158/1078-0432.CCR-21-4413. pmid: 35536547
[16]	Zhang W, Lu X, Cui P, et al. Phase Ⅰ/Ⅱ clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer[J]. Cancer Immunol Immunother, 2019, 68(1): 121-130. DOI: 10.1007/s00262-018-2257-2. pmid: 30306202
[17]	Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial[J]. Nat Med, 2022, 28(8): 1630-1639. DOI: 10.1038/s41591-022-01897-x. pmid: 35864254
[18]	Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer[J]. Nature, 2023, 618(7963): 144-150. DOI: 10.1038/s41586-023-06063-y.
[19]	Tchernonog E, Moignet A, Anota A, et al. Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress[J]. Haematologica, 2024, 109(8): 2401-2419. DOI: 10.3324/haematol.2022.282363.
[20]	文凤, 李秋. CAR-T在消化道实体瘤治疗中的研究进展与展望[J]. 延安大学学报(医学科学版), 2023, 21(4): 1-8. DOI: 10.19893/j.cnki.ydyxb.2023-0191.
[21]	Suh YS, Na D, Lee JS, et al. Comprehensive molecular characteri-zation of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas[J]. Ann Surg, 2022, 275(4): 706-717. DOI: 10.1097/SLA.0000000000004303.
[22]	Ter Veer E, van den Ende T, Creemers A, et al. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis[J]. Acta Oncol, 2018, 57(12): 1599-1604. DOI: 10.1080/0284186X.2018.1503421. pmid: 30264641
[23]	Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]. Lancet, 2023, 402(10418): 2197-2208. DOI: 10.1016/S0140-6736(23)02033-0. pmid: 37871604
[24]	Rivera F, Izquierdo-Manuel M, García-Alfonso P, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase Ⅱ trial[J]. Eur J Cancer, 2021, 145: 158-167. DOI: 10.1016/j.ejca.2020.12.005.
[25]	Tintelnot J, Stein A, Al-Batran SE, et al. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase Ⅱ trial of the AIO study group(AIO STO 0321)[J]. Front Oncol, 2023, 13: 1272175. DOI: 10.3389/fonc.2023.1272175.
[26]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369. DOI: 10.3760/cma.j.cn371439-20231130-00063.
[27]	Shitara K. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-gastric01 study[J]. Future Oncol, 2024, 20(2): 59-70. DOI: 10.2217/fon-2023-0245.
[28]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757. DOI: 10.3760/cma.j.cn371439-20230911-00141.
[29]	Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial[J]. Lancet Oncol, 2020, 21(8): 1066-1076. DOI: 10.1016/S1470-2045(20)30326-0. pmid: 32653053
[30]	Augustin JE, Soussan P, Bass AJ. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma[J]. Ann Oncol, 2022, 33(11): 1134-1148. DOI: 10.1016/j.annonc.2022.08.001. pmid: 35963482
[31]	Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46. DOI: 10.1158/2159-8290.CD-21-1059. pmid: 35022204
[32]	Xu RH, Zhang Y, Pan H, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(12): 1015-1024. DOI: 10.1016/S2468-1253(21)00313-7.
[33]	Zhang TQ, Geng ZJ, Zuo MX, et al. Camrelizumab(a PD-1 inhibitor) plus apatinib(an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in barcelona clinic liver cancer stage C (TRIPLET): a phase Ⅱ study[J]. Signal Transduct Target Ther, 2023, 8(1): 413. DOI: 10.1038/s41392-023-01663-6.
[34]	Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(3): 420-435. DOI: 10.1016/S1470-2045(18)30791-5. pmid: 30718072
[35]	Maron SB, Moya S, Morano F, et al. Epidermal growth factor receptor inhibition in epidermal growth factor receptor-amplified gastroesophageal cancer: retrospective global experience[J]. J Clin Oncol, 2022, 40(22): 2458-2467. DOI: 10.1200/JCO.21.02453.
[36]	Maron SB, Alpert L, Kwak HA, et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-Amplified gastroesophageal adenocarcinoma[J]. Cancer Discov, 2018, 8(6): 696-713. DOI: 10.1158/2159-8290.CD-17-1260.
[37]	Moosavi F, Giovannetti E, Peters GJ, et al. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer[J]. Crit Rev Oncol Hematol, 2021, 160: 103234. DOI: 10.1016/j.critrevonc.2021.103234.
[38]	Kim HS, Kim JH, Jang HJ. Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review[J]. J Cancer, 2019, 10(11): 2560-2567. DOI: 10.7150/jca.29184.
[39]	Catenacci DVT, Rasco D, Lee J, et al. Phase Ⅰ escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma[J]. J Clin Oncol, 2020, 38(21): 2418-2426. DOI: 10.1200/JCO.19.01834. pmid: 32167861
[40]	Hashimoto I, Oshima T. Claudins and gastric cancer: an overview[J]. Cancers (Basel), 2022, 14(2): 290. DOI: 10.3390/cancers14020290.
[41]	Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase Ⅱ study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J]. Ann Oncol, 2021, 32(5): 609-619. DOI: 10.1016/j.annonc.2021.02.005. pmid: 33610734
[42]	Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6): 1189-1198. DOI: 10.1038/s41591-022-01800-8. pmid: 35534566
[43]	Kim JH, Zang DY, Jang HJ, et al. A bayesian network meta-analysis on systemic therapy for previously treated gastric cancer[J]. Crit Rev Oncol Hematol, 2021, 167: 103505. DOI: 10.1016/j.critrevonc.2021.103505.
[44]	Lorenzen S, Knorrenschild JR, Pauligk C, et al. Phase Ⅲ rando-mized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)[J]. Int J Cancer, 2020, 147(9): 2493-2502. DOI: 10.1002/ijc.33025.

胃癌及食管胃结合部癌免疫及靶向治疗研究进展

Research progress in immunotherapy and targeted therapy for gastric cancer and esophagogastric junction cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

编辑推荐

Metrics

本文评价

[1]	詹海峰, 王文学, 耿嘉蔚. 晚期结直肠癌精准分子靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 601-605.
[2]	刘文会, 殷平, 戚洁. 血清G-17、sB7-H3、DKK1检测对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(8): 498-503.
[3]	刘晶, 张俊. 放射性碘难治性分化型甲状腺癌再分化治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 464-467.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[7]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[8]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[9]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[10]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[11]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[12]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[13]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[14]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.